Generic Drugs

Analysts said that the US President Trump’s latest executive order on drug price control could indirectly discourage Indian drug makers from pursuing specialty business in America.

India rejects European FTA bloc's 'data exclusivity' demand to protect generic drug firms' interest

India's generic drug industry is estimated at about USD 25 billion and the country exports 50 per cent of its produce.

Indian pharma's growth expectations are trending downwards

The market grew by just 3.5 percent in November 2023. Lower price hikes and competition from generics are the main obstacles to higher growth

Why NMC’s proposal on generic drugs, professional conduct of doctors was a wrong prescription

Doctors claimed that prescribing generic drugs without ensuring their quality and safety could compromise patient care and outcomes, and expose them to legal and ethical risks

NMC puts on hold its regulations mandating doctors to prescribe generic drugs, bar them from endorsing any drug brand

They said the regulation barring doctors from attending conferences sponsored by pharma companies warrants reconsideration and also demanded that associations and organisations should be exempted from the purview of NMC guidelines.

Sun Pharma's investors face a risk from India's unbranded generic drug push

Its large presence in India's branded generic drug market exposes it the most to a risk from trade generics. But other major pharma companies are at risk too

Chart of the Day: Pharma market growth momentum healthy, but risks lurk

While drug sales continue to grow at a healthy pace the market is seeing higher competition from trade generics

Zydus Lifesciences gets final approval from USFDA for Azithromycin tablets

The approval by the US Food and Drug Administration (USFDA) is for manufacturing and marketing of Azithromycin tablets 500 mg strength, Zydus Lifesciences said in a regulatory filing.

Generic versions of diabetes drug Sitagliptin now available at govt stores at affordable prices

The drug can be used for majority of the patients suffering from type 2 diabetes  

Novartis to spin off generics business Sandoz next year

Novartis (NOVN.S) announced on Thursday that it intended to spin off its generics division Sandoz in order to narrow its focus on its patented prescription drugs.

Endless growth prospects for generics in India, Jan Aushadhi pharmacies aim to match growing demand: PMBI CEO Ravi Dadhich

Having seen an exponential rise in the number of outlets opening since 2015, the government, through Jan Aushadhi Kendras, aims to make the quality generic medicines available to every citizen

Monthly revenue from Jan Aushadhi shops cross Rs 100 crore for first time

These stores, that sell, generic medicines are already operational in 739 districts of the country

India woos ASEAN with generics production, vaccines; wants support in IPR waiver

Apart from securing the support of ASEAN nations for the global intellectual property waiver for COVID vaccines, the move is also aimed at pulling closer the traditional partners in the bloc, who have become close to China, sources say

Veterans Unpacked | D.S. Brar: "Your network is your net worth, and your credibility is your currency"

His advice to young leaders: "Focus on relationships and building trust with your customers, your partners and your employees."

Reporter's Take | How safe are generic drugs?

Moneycontrol’s Shraddha Sharma talks to Viswanath Pilla to know more about the debate and if there are solutions to it.

Lupin denies price manipulation allegations, says will defend antitrust lawsuit in US

Lupin was named as a defendant with respect to 11 generic drugs for alleged price manipulation.

Comment | Cipla takes a calculated risk with generic Sensipar launch

Cipla’s launch of a blockbuster drug made by Amgen even while litigation is ongoing is a risky affair. Here’s why Cipla may have taken a calculated risk

Comment | US FDA to get a new chief, watch for side effects on pharma shares

The US FDA has been driving generic drug approvals under its current commissioner. His resignation raises a question mark on whether life could change for Indian pharmaceutical companies

Modi’s proposed law on docs using generic name in prescriptions gets MSF vote

MSF said the unhealthy nexus between doctors and pharma companies encourages over prescription of expensive medicines.

Torrent Pharma to acquire clutch of generic brands from Novartis

As global drug makers are exiting low priority brands, their Indian counterparts are lapping up the opportunity buying established products at perhaps low valuations.

Despite regulatory issues, pharma regulators positive on outlook

There's no end in sight for the Indian pharmaceutical industry's struggles with domestic and foreign drug regulators. It's true that quite a few companies have received clean chits from regulators in the US, UK and Europe. However, at the same time, new issues have also been cropping up with disturbing frequency.

Q3 results: Five trends to watch out from Indian drugmakers

Analysts predict Q3 to be a tough quarter with revenue growth moderating to 11.7 percent in October-December period compared to 18.4 percent compounded annual growth rate (CAGR) over last 10 years

Serial testers, hasty checks: India's flawed generic drug trials

HYDERABAD (Reuters) - Vasudeva Prakash left his job as a mechanic in Hyderabad three years ago for what he calls a more lucrative career: taking part in clinical trials on generic drugs.

Pharma industry eyes generic drug exports to Japanese market

Appaji said the country exports its one-third pharma products to US alone. "But we are looking at more opportunities in Japan and Latin American markets," he said.